The most common adverse events of grade @ or worse were anaemia ( @ -LSB- @ % -RSB- of @ patients in the gefitinib group and five -LSB- @ % -RSB- of @ patients in the placebo group ) and neutropenia ( nine -LSB- @ % -RSB- and seven -LSB- @ % -RSB- ) .